Heiniö, C.; Clubb, J.; Kudling, T.; Quixabeira, D.; Cervera-Carrascon, V.; Havunen, R.; Grönberg-Vähä-Koskela, S.; Santos, J.M.; Tapper, J.; Kanerva, A.;
et al. Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers. Diseases 2022, 10, 52.
https://doi.org/10.3390/diseases10030052
AMA Style
Heiniö C, Clubb J, Kudling T, Quixabeira D, Cervera-Carrascon V, Havunen R, Grönberg-Vähä-Koskela S, Santos JM, Tapper J, Kanerva A,
et al. Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers. Diseases. 2022; 10(3):52.
https://doi.org/10.3390/diseases10030052
Chicago/Turabian Style
Heiniö, Camilla, James Clubb, Tatiana Kudling, Dafne Quixabeira, Victor Cervera-Carrascon, Riikka Havunen, Susanna Grönberg-Vähä-Koskela, João Manuel Santos, Johanna Tapper, Anna Kanerva,
and et al. 2022. "Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers" Diseases 10, no. 3: 52.
https://doi.org/10.3390/diseases10030052
APA Style
Heiniö, C., Clubb, J., Kudling, T., Quixabeira, D., Cervera-Carrascon, V., Havunen, R., Grönberg-Vähä-Koskela, S., Santos, J. M., Tapper, J., Kanerva, A., & Hemminki, A.
(2022). Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers. Diseases, 10(3), 52.
https://doi.org/10.3390/diseases10030052